Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial.
Sonneveld P, van der Holt B, Segeren CM, Vellenga E, Croockewit AJ, Verhoe GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Westveer PH, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Sonneveld P, et al. Among authors: westveer ph. Haematologica. 2007 Jul;92(7):928-35. doi: 10.3324/haematol.11168. Haematologica. 2007. PMID: 17606443 Free article. Clinical Trial.
Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM, Westveer PH, Poddighe PJ, Verhoef GE, Sonneveld P; Dutch-Belgian Haemato-Oncology Cooperative Study Group (HOVON); Dutch Working Party on Cancer Genetics and Cytogenetics (NWCGC). Wu KL, et al. Among authors: westveer ph. Br J Haematol. 2007 Feb;136(4):615-23. doi: 10.1111/j.1365-2141.2006.06481.x. Br J Haematol. 2007. PMID: 17223915 Free article. Clinical Trial.
Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM.
Lokhorst HM, Segeren CM, Verdonck LF, van der Holt B, Raymakers R, van Oers MH, Barge RM, Schouten HC, Westveer PH, Steijaert MM, Cornelissen JJ, Sonneveld P; Dutch-Belgian Hemato-Oncology Cooperative Group. Lokhorst HM, et al. Among authors: westveer ph. J Clin Oncol. 2003 May 1;21(9):1728-33. doi: 10.1200/JCO.2003.04.033. J Clin Oncol. 2003. PMID: 12721248 Clinical Trial.
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.
Deenik W, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Kluin-Nelemans HC, Verdonck LF, Ferrant A, Schattenberg AV, Janssen JJ, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Westveer PH, Beverloo HB, Valk P, Löwenberg B, Ossenkoppele GJ, Cornelissen JJ. Deenik W, et al. Among authors: westveer ph. Blood. 2008 Mar 1;111(5):2581-8. doi: 10.1182/blood-2007-08-107482. Epub 2008 Jan 2. Blood. 2008. PMID: 18172005 Free article. Clinical Trial.
High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study.
Deenik W, van der Holt B, Verhoef GE, Schattenberg AV, Verdonck LF, Daenen SM, Zachée P, Westveer PH, Smit WM, Wittebol S, Schouten HC, Löwenberg B, Ossenkoppele GJ, Cornelissen JJ. Deenik W, et al. Among authors: westveer ph. Ann Hematol. 2007 Feb;86(2):117-25. doi: 10.1007/s00277-006-0186-1. Epub 2006 Oct 10. Ann Hematol. 2007. PMID: 17031690 Free PMC article. Clinical Trial.
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
Ossenkoppele GJ, Graveland WJ, Sonneveld P, Daenen SM, Biesma DH, Verdonck LF, Schaafsma MR, Westveer PH, Peters GJ, Noordhuis P, Muus P, Selleslag D, van der Holt B, Delforge M, Löwenberg B, Verhoef GE; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Ossenkoppele GJ, et al. Among authors: westveer ph. Blood. 2004 Apr 15;103(8):2908-13. doi: 10.1182/blood-2003-07-2195. Epub 2003 Dec 4. Blood. 2004. PMID: 15070662 Free article. Clinical Trial.
Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients.
Goldschmidt H, Sonneveld P, Cremer FW, van der Holt B, Westveer P, Breitkreutz I, Benner A, Glasmacher A, Schmidt-Wolf IG, Martin H, Hoelzer D, Ho AD, Lokhorst HM; HOVON; GMMG. Goldschmidt H, et al. Ann Hematol. 2003 Oct;82(10):654-9. doi: 10.1007/s00277-003-0685-2. Epub 2003 Jul 4. Ann Hematol. 2003. PMID: 12845480 Clinical Trial. No abstract available.
Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.
Minnema MC, Breitkreutz I, Auwerda JJ, van der Holt B, Cremer FW, van Marion AM, Westveer PH, Sonneveld P, Goldschmidt H, Lokhorst HM. Minnema MC, et al. Among authors: westveer ph. Leukemia. 2004 Dec;18(12):2044-6. doi: 10.1038/sj.leu.2403533. Leukemia. 2004. PMID: 15470485 Clinical Trial. No abstract available.